Log In
Print
BCIQ
Print
Print this Print this
 

Daliresp, Daxas, roflumilast (APTA-2217)

  Manage Alerts
Collapse Summary General Information
Company Takeda Pharmaceutical Co. Ltd.
DescriptionNon-steroidal phosphodiesterase-4 (PDE-4) inhibitor
Molecular Target Phosphodiesterase-4 (PDE-4)
Mechanism of ActionPhosphodiesterase-4 (PDE-4) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD); Treat symptomatic chronic obstructive pulmonary disease (COPD)
Regulatory Designation

Partner

Actavis plc; Merck & Co. Inc.; Mitsubishi Tanabe Pharma Corp.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today